The FDA has approved Korlym (mifepristone)(formerly Corlux) from Corcept Therapeutics to control high blood sugar levels (hyperglycemia) in adults with endogenous Cushing’s syndrome. This drug was approved for use in patients with endogenous Cushing’s syndrome who have Type 2 Diabetes or glucose intolerance and are not candidates for surgery or who have not responded to prior surgery. Korlym should never be used (contraindicated) by pregnant women. Prior to FDA’s approval of Korlym, there were no approved medical therapies for the treatment of endogenous Cushing’s syndrome. Mifepristone already is marketed in the US under the name Mifeprex by Danco Laboratories as a drug to induce abortions in the first 49 days of pregnancy.